RxSight (RXST) announced that Shelley Thunen, the company’s CFO, is transitioning from her role. Thunen will remain with the company until the sooner of the appointment of her successor or January 31, 2026. Thunen has agreed to support the company as a consultant subsequent to the transition.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight Announces Executive Leadership Reorganization and New Appointments
- RxSight price target raised to $10 from $9 at Morgan Stanley
- RxSight Earnings Call: Mixed Signals Amid Growth and Challenges
- RxSight price target raised to $10 from $8 at Stifel
- RxSight price target raised to $9 from $8 at JPMorgan